First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Linda M. Liau(University of California, Los Angeles), Santosh Kesari(Cancer Institute (WIA)), Scott Lindhorst, Steven A. Toms(Geisinger Health System), Dietmar Krex, William G. Loudon(St. Joseph Hospital), Paul Duic(Winthrop-University Hospital), Heinrich Elinzano(Providence College), Charles Cobbs(University of California, San Francisco), Hans-Joerg Meisel(BG Klinikum Bergmannstrost Halle), Tobias Walbert(Henry Ford Health System), Rekha Chaudhary(University of Cincinnati), David Mathieu(Hôpital Fleurimont), Kevin O. Lillehei(University of Colorado Health), Simon Khagi(University of North Carolina at Chapel Hill), Jian Campian, Daniela A. Bota(University of California, Irvine), Jose Lutzky, Steven Brem(University of Pennsylvania), John Trusheim(Abbott Northwestern Hospital), David Avigan(Beth Israel Deaconess Medical Center), Jai Grewal(Winthrop-University Hospital), Clement Pillainayagam(Rush University Medical Center), Gabriele Schackert(University Hospital Carl Gustav Carus), Julian K. Wu(Tufts Medical Center), Robert Aiken(Rutgers, The State University of New Jersey), Tom Mikkelsen(Henry Ford Health System), Samuel Goldlust(Hackensack University Medical Center), Arnold B. Etame(Moffitt Cancer Center), Reid C. Thompson(Neurological Surgery), Yaron A. Moshel(Overlook Medical Center), Steven R. Abram(Saint Thomas Health), Stacy D. D’Andre(Sutter Institute for Medical Research), Jason Heth(University of Michigan), Andrew Brenner(The University of Texas at San Antonio Health Science Center), Edward J. Dropcho(Indiana University Health), Kevin A. Walter(University of Rochester Medical Center), Fábio M. Iwamoto(Columbia University), Jana Portnow(City of Hope), Andrew E. Sloan(University of Southern California), Sarah Taylor(National Institutes of Health), David D. Tran(University of Florida), Matthew G. Ewend, Michael Salacz(The University of Kansas Cancer Center), Raphael P. Davis(Stony Brook University), Francois J. Geoffroy(Mayo Clinic), Karen Fink(McGill University), Lyndon J. Kim(Thomas Jefferson University), Keyoumars Ashkan(King's College London), Christopher Duma(Hoag Memorial Hospital Presbyterian)
Cited by 540
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k